Texas Yale Capital Corp. Grows Position in AstraZeneca plc (AZN)

Texas Yale Capital Corp. boosted its position in shares of AstraZeneca plc (NYSE:AZN) by 35.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,580 shares of the company’s stock after purchasing an additional 4,580 shares during the period. Texas Yale Capital Corp.’s holdings in AstraZeneca were worth $610,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in AZN. WFG Advisors LP lifted its position in shares of AstraZeneca by 36.0% in the second quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock worth $127,000 after buying an additional 984 shares during the last quarter. Valeo Financial Advisors LLC acquired a new stake in shares of AstraZeneca in the third quarter worth about $133,000. Calton & Associates Inc. acquired a new stake in shares of AstraZeneca in the fourth quarter worth about $181,000. Wealthcare Advisory Partners LLC acquired a new stake in shares of AstraZeneca in the third quarter worth about $184,000. Finally, Neumann Capital Management LLC acquired a new stake in shares of AstraZeneca in the fourth quarter worth about $202,000. 14.75% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca plc (NYSE AZN) opened at $33.86 on Wednesday. The company has a debt-to-equity ratio of 0.93, a current ratio of 0.80 and a quick ratio of 0.62. The company has a market capitalization of $86,342.81, a PE ratio of 14.37, a PEG ratio of 2.06 and a beta of 0.70. AstraZeneca plc has a 12 month low of $28.43 and a 12 month high of $36.70.

AstraZeneca (NYSE:AZN) last posted its quarterly earnings data on Friday, February 2nd. The company reported $1.30 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.86. The business had revenue of $5.78 billion for the quarter, compared to analyst estimates of $5.49 billion. AstraZeneca had a return on equity of 34.74% and a net margin of 13.36%. The firm’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.21 earnings per share. research analysts predict that AstraZeneca plc will post 1.67 EPS for the current fiscal year.

The firm also recently disclosed a semiannual dividend, which will be paid on Monday, March 19th. Stockholders of record on Friday, February 16th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Thursday, February 15th. This represents a dividend yield of 5.62%. AstraZeneca’s payout ratio is presently 57.81%.

A number of analysts have weighed in on the company. BMO Capital Markets reaffirmed a “buy” rating and issued a $38.00 price target on shares of AstraZeneca in a research report on Tuesday, November 7th. Sanford C. Bernstein boosted their price target on AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. Leerink Swann boosted their price target on AstraZeneca from $36.00 to $38.00 and gave the stock a “market perform” rating in a research report on Tuesday, February 6th. Citigroup raised AstraZeneca to a “buy” rating in a research report on Wednesday, October 18th. Finally, Zacks Investment Research raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Monday, January 22nd. Three research analysts have rated the stock with a sell rating, eight have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. AstraZeneca has a consensus rating of “Hold” and a consensus price target of $35.20.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/02/14/texas-yale-capital-corp-grows-position-in-astrazeneca-plc-azn.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply